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STUDY PROTOCOL

A cluster randomized controlled trial
for a multi‑level, clinic‑based smoking
cessation program with women in Appalachian
communities: study protocol for the “Break Free”
program
Joanne G. Patterson1,2* , Tia N. Borger3, Jessica L. Burris3, Mark Conaway4, Robert Klesges4,13, Amie Ashcraft5,
Lindsay Hauser6, Connie Clark6, Lauren Wright5, Sarah Cooper7, Merry C. Smith7, Mark Dignan8,9,
Stephenie Kennedy‑Rea10,11, Electra D. Paskett1,2,12, Roger Anderson4,13 and Amy K. Ferketich1,2

Abstract
Background: The cervical cancer burden is high among women living in Appalachia. Cigarette smoking, a cervical
cancer risk factor, is also highly prevalent in this population. This project aims to increase smoking cessation among
women living in Appalachia by embedding a smoking cessation program within a larger, integrated cervical cancer
prevention program.
Methods: The broader program, the Take CARE study, is a multi-site research collaborative designed to address three
risk factors for cervical cancer incidence and mortality: tobacco use, human papillomavirus (HPV) infection, and cervi‑
cal cancer screening. Break Free is a primary care clinic-based implementation program that aims to promote smoking
cessation among female smokers in Appalachia by standardizing clinical practice protocols. Break Free includes: (1)
implementation of a tobacco user identification system in the Electronic Health Record, (2) clinic staff and provider
training on the Ask, Advise and Refer (AAR) model, (3) provider implementation of AAR to identify and treat women
who want to quit smoking within the next 6 months, (4) facilitated access to cessation phone counseling plus phar‑
macotherapy, and (5) the bundling of Break Free tobacco cessation with HPV vaccination and cervical cancer screen‑
ing interventions in an integrated approach to cervical cancer prevention. The study spans 35 Appalachian health
clinics across 10 healthcare systems. We aim to enroll 51 adult female smokers per health system (total N = 510).
Baseline and follow-up data will be obtained from participant (provider and patient) surveys. The primary outcome
is self-reported 12-month point prevalence abstinence among enrolled patients. All randomized patients are asked
to complete follow-up surveys, regardless of whether they participated in tobacco treatment. Data analysis of the
primary aims will follow intent-to-treat methodology. Secondary outcomes will assess program implementation and
cost effectiveness.
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Discussion: Addressing high tobacco use rates is critical for reducing cervical cancer morbidity and mortality among
women living in Appalachia. This study evaluates the implementation and effectiveness of a smoking cessation pro‑
gram in increasing smoking cessation among female smokers. If results demonstrate effectiveness and sustainability,
implementation of this program into other health care clinics could reduce both rates of smoking and cervical cancer.
Trial registration NCT04340531 (April 9, 2020)
Keywords: Smoking cessation, Rural health, Cervical cancer prevention, Implementation science, Clinic-based
interventions

Background
Appalachia—a mountainous region that spans 13 states
and is populated by approximately 35.7 million individuals [1]—has a higher burden of cancer than other
regions in the United States (US). The cancer mortality
rate in Appalachia is 10% higher than the national rate,
and tobacco-related cancers are highly prevalent in this
region [2–4]. Cervical cancer, a preventable condition, is
23% more prevalent in Appalachian regions and women
are 25% more likely to die from cervical cancer in this
region than their non-Appalachian counterparts [2–4].
These regional disparities are alarming as national incidence rates for cervical cancer have consistently been
declining [5] with the growth of initiatives to address
modifiable risk factors (e.g., smoking, human papillomavirus (HPV) infection rates, access to cervical cancer
screening). In contrast, women in Appalachia continue
to experience disparities across a multiplicity of cervical
cancer risk factors [6] including disparately high smoking rates [7], low uptake of HPV vaccination [8], and low
rates of cervical cancer screening [9]. To reduce cervical
cancer morbidity and mortality in Appalachia, implementation research is needed to test the effectiveness
and sustainability of evidence-based interventions that
address cervical cancer risk factors.
Cigarette smoking is a modifiable risk factor for cervical cancer. Studies from the US, Europe, and China
indicate that female smokers are at increased risk of
cervical cancer and/or pre-cancerous lesions [10–12].
Smoking prevalence rates in Appalachian communities are elevated; for example, in Appalachian Ohio,
23–44% of adults report current smoking [13] and in
Appalachian Kentucky current smoking prevalence is
33% rate [14]; over twice the national rate [15]. Multilevel barriers to smoking cessation exist in Appalachia.
Structural determinants (e.g., high poverty rates and
low educational attainment), pro-tobacco social norms,
underinvestment in smoking prevention, and limited
access to cessation treatment drive cessation disparities at the population level [16–18]. However, individual-level determinants including high perceived stress,
cessation ambivalence, and distrust in pharmacotherapy may be additional barriers to smoking cessation in

this population [19–21]. Identifying culturally acceptable, effective, and scalable interventions is critical for
increasing cessation among women living in Appalachia. Undoubtedly, such interventions could have a
significant, positive impact on reducing cervical cancer
disparities among women living in Appalachia, in addition to the many tobacco-related chronic diseases that
are widespread in this region [22].
The US Public Health Service Clinical Practice Guideline, Treating Tobacco Use and Dependence [23], recommends that all healthcare systems and providers
systematically assess and document tobacco use, adopt
motivational techniques to encourage quitting, and
provide evidence-based tobacco cessation. Healthcare
providers can be effective advocates for smoking cessation, with brief advice alone increasing the odds of quit
attempts and abstinence [24]. However, only 50–75% of
providers regularly screen patients for tobacco [25–28]
and just over half of smokers report being advised to quit
smoking by their providers [27–29]. As such, developing
clinic-based interventions that increase the rate at which
smokers are identified, advised to quit, and provided or
referred for cessation treatment is critical for eliminating
tobacco-related health disparities among women living in
Appalachia.
Primary care clinics are an ideal setting to reach and
engage women in smoking cessation treatment, as more
than 70% of smokers visit a provider each year [30].
Implementing the Clinical Practice Guideline can be
challenging, however, for primary care practices and providers, due to lack of training, limited knowledge about
the recommendations, lack of patient motivation to quit,
and inadequate billing and reimbursement systems [31–
34]. In Appalachia, these challenges are compounded
by limited access to comprehensive cessation programs
that offer sustained assistance, inadequate patient education resources, and practical barriers to follow-up [35].
Barriers notwithstanding, training that targets providers’ knowledge, attitudes, and practice behaviors can
increase adherence to the Clinical Practice Guideline
[23] and increase smoking abstinence at the patient level
[24]. By giving providers tools to change clinical practice
behaviors, implementing provider-targeted educational
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interventions may be an effective strategy for reducing
smoking among women living in Appalachia.
To address the high rates of both cervical cancer and
smoking in Appalachian women, a transdisciplinary team
of investigators developed the Take CARE (Clinical Avenues to Reach Health Equity) study, a multi-site research
collaborative comprising four universities and participating clinics located in Appalachian counties of Kentucky,
Ohio, Virginia, and West Virginia. Take CARE is designed
to address the burden of cervical cancer incidence and
mortality in Appalachia through the delivery of an integrated clinic-based cancer prevention program. Funded
by the National Institutes of Health (P01CA229143), the
Take CARE study focuses on the major causes of cervical
cancer including: tobacco smoking, HPV infection, and
lack of cervical cancer screening. Research in this collaborative spans both qualitative and experimental designs
and involves community participation and engagement.
Study endpoints include measures of intervention implementation, quality improvement processes, and client
outcomes. This paper describes the study protocol for
Break Free, one of three initiatives in the Take CARE
study (ClinicalTrials.gov ID: NCT04340531). Break
Free is an evidence-based smoking cessation intervention designed to address the lack of provider-led tobacco
assessment and intervention in Appalachian healthcare
clinics and, ultimately, increase smoking cessation rates
among women living in Appalachia. The aims of this
study are to determine: (1) effectiveness of the Break Free
intervention, (2) satisfaction with the intervention, and
(3) sustainability of the intervention.

Methods
This protocol (Version 3, 11/23/2021) has been written
according to the recommendations of the SPIRIT 2013
statement, a guideline that defines the standard elements
of a protocol (see Additional file 1). Any modifications
to the protocol are discussed during biweekly research
team meetings and then communicated to the Take
CARE Steering Committee, Institutional Review Board
(IRB), trial registries, and participants as needed by IRBapproved study team members.
Study overview

We are conducting a Type III hybrid effectiveness-implementation study to evaluate a multilevel smoking cessation program for women in Appalachia. Type III hybrid
effectiveness-implementation study designs focus on
assessing implementation outcomes while also assessing
clinical outcomes associated with study implementation.
Our primary study goal is to test the implementation of
a clinic-based, supported tobacco cessation program in
Appalachia, using measures of adoption of and fidelity to
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the intervention. However, we are also measuring patientlevel effects of the intervention on smoking cessation
rates. The evaluation will occur over 5 years and includes
health system-, provider- and patient-level interventions
for participating clinics from 10 health systems. The
multilevel program components consist of recommendations from the Clinical Practice Guideline [23]. These
include recommendations that health systems implement
a tobacco user identification system at the clinic level
(ask about, and document, smoking status) and providers
advise all smokers to quit and refer those ready to quit to
Break Free phone counseling, which provides supported
smoking cessation. Notably, Break Free phone counseling
provides treatment to women who plan to quit within six
months, allowing the content to be tailored to the level of
readiness to quit for each individual participant.
Break Free

Break Free was developed through our prior work with
health systems in Appalachian regions of Virginia [36]
and Ohio [26, 37–39] and modified by the study team to
have broad applicability across diverse primary care settings. Break Free is one of three initiatives in the Take
CARE program. This overarching program also includes
four cores (shared resources): Administrative, Survey
and Data Collection, Intervention and Consortium, and
Biostatistics and Evaluation. The Administrative Core
supports the Take CARE program by providing leadership in program planning and development, implementing communication channels, and facilitating integration
of the Take CARE Program cores and the three research
projects. The Survey and Data Collection Core will assist
initiatives with their data collection activities, develop a
database of indicators and measures to be applied across
all three research projects, and provide support for interactions with clinic electronic health systems and data
capture. The Intervention and Consortium Core will lead
efforts to develop and deliver the interventions being
tested in each initiative, and maintain communications
with community partners. Finally, the Biostatistics and
Evaluation Core will provide investigators with a centralized resource to plan, implement, monitor, and analyze
data from all three initiatives and the overall Take CARE
program, including cost-effectiveness. Information on
how each of the Take CARE cores will support Break Free
project planning, implementation, data collection and
analysis is described below in the context of study design,
data collection, analysis, and dissemination.
Prior to launching the Take CARE program, lead study
investigators proactively engaged executive leadership
from each health system to obtain their commitment to
Take CARE and its three initiatives, including Break Free.
Throughout each phase of the study, lead investigators
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will maintain contact with health system leadership via
regular communication with medical directors of participating clinics/health systems. At the end of the study, we
will also present overall results from Take CARE, including study-specific results from Break Free, to the boards
of participating health systems. Each initiative in Take
CARE is also supported by a Community Advisory Board
comprised of leaders from diverse community-based
institutions. This Board will inform best practices for
project implementation, including issues of access and
barriers to uptake, as well as methods for ensuring sustainability beyond the grant funding period.
Break Free includes clinic, provider, and patient components (Fig. 1). During the year prior to launching Break
Free, our team conducted community, health system,
and clinic assessments; focus groups; and key informant interviews to refine the multilevel intervention components and develop materials. Break Free begins in the
clinic with brief provider-delivered cessation counseling.
During a routine medical visit, providers ask all patients
about their tobacco use and document tobacco use and
smoking status in the electronic health record. Providers
then advise smokers to quit and assess their readiness to
quit. Smokers who are ready to quit in the next 6 months
receive a prescription for pharmacotherapy and a referral
to the Break Free Enrollment Specialist. Thus, Break Free
follows the Ask, Advise, and Refer (AAR) smoking cessation model [23].
Clinic components

Each participating clinic is asked to implement a tobacco
user identification system [23] in their existing electronic
health record that meets the very basic requirement of
prompting providers to ask patients about tobacco use.
The Survey and Data Collection core will support each
clinic to evaluate and update their EHR as need to capture tobacco use information. Each clinic is also encouraged to train at least one employee as a Clinic Champion

Fig. 1 Break Free program components
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and a Break Free Enrollment Specialist. The Clinic Champion is someone who advocates for the integration of
evidence-based smoking cessation treatment into the
clinical workflow and keeps clinic staff motivated to promote smoking cessation among their patient population.
The Enrollment Specialist is a staff person who acts as a
liaison between providers and Break Free phone counseling. After a provider refers a patient to Break Free
phone counseling, the Enrollment Specialist explains
the details of the program, distributes patient education
materials, and connects the patient with a tobacco treatment specialist (TTS).
Provider components

All providers who are directly involved in patient care
(e.g., physicians, advanced practice registered nurses)
receive a 30–60-min training on how to deliver brief
cessation counseling in the clinic [24]. Provider training is delivered via Zoom or Teams (due to the ongoing COVID-19 pandemic; in the future trainings may
take place in person) once per intervention phase and
is scheduled at a time convenient for the clinic. Providers who are unable to attend the training are offered the
recording of the online training. The basic training materials were developed from the Rx for Change© program
materials [40] and modified to include additional information about smoking in Appalachia, national data about
readiness to quit smoking and use of pharmacotherapy,
and other information that is relevant to our theoretical
model, the Theory of Planned Behavior [41, 42].
The provider training targets relevant theoretical constructs that are hypothesized to predict providers’ intentions to provide brief cessation counseling to patients
using the AAR method. Specifically, content addresses
providers’: (1) normative beliefs by reviewing smoking
prevalence in Appalachia and providing an introduction to the Clinical Practice Guideline; (2) behavioral
beliefs by describing the efficacy of pharmacotherapy and
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behavioral counseling; and (3) perceived behavioral control by modeling how to implement the AAR model and
detailing how to prescribe pharmacotherapy to patients
ready to quit smoking. Providers also receive pocket
cards (see Additional file 1) that outline Break Free
phone counseling eligibility criteria and pharmacotherapy options for smoking cessation. Healthcare providers
are essential to Break Free’s success. They are expected
to deliver the AAR model during patient encounters.
Thus, providers are to ask about tobacco use, advise users
to quit, and refer smokers who are interested in quitting to Break Free phone counseling via the Enrollment
Specialist.
The Break Free Clinic Champions and Enrollment
Specialists also attend the provider training to learn the
details of the intervention. Following this, Clinic Champions and Enrollment Specialists complete their own
20–30-min training session on Teams or Zoom. This session focuses on the tasks they complete to enroll participants into Break Free phone counseling and sustain Break
Free provider implementation of AAR and TTS-delivered
phone counseling in the clinic after the study ends. For
example, Break Free Enrollment Specialists learn about
the content of the educational materials, how to track
patient referrals, and how to contact the TTS. Checklists
are created for Clinic Champions and Break Free Enrollment Specialists to use while working with the Break Free
program.
Booster sessions are offered to each clinic. Topics
include how to better engage smokers in conversations
about cessation and how to bill for smoking cessation
counseling (this latter topic will be offered during the
sustainability phase).
Patient components

Smokers enrolled in Break Free receive customized
patient educational materials, phone counseling, and
pharmacotherapy. The patient education materials
consist of an informational booklet that describes the
benefits of smoking cessation, nicotine withdrawal symptoms, tips for coping with withdrawal and maintaining
abstinence, and pharmacotherapy, and a wallet-sized
self-monitoring booklet wherein patients record basic
information about their smoking behavior (e.g., date,
time, circumstances) as they attempt to understand their
usage patterns and make quit attempts (see Additional
file 1).
To ensure acceptability and health literacy of materials, we conducted focus groups with community members from West Virginia and rural, Appalachian Ohio,
Kentucky, and Virginia regions. In each state, two successive focus groups occurred. In the first, participants
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provided feedback on baseline patient surveys and publicly available smoking cessation materials created by Rx
for Change© [40] and the University of Virginia Cancer
Center. We used participant feedback to create the customized materials for Break Free. In the second focus
group, the participants reviewed drafted Break Free
materials, which were then refined.
Cessation phone counseling is led by a trained TTS. A
study-supported TTS is available to all participating clinics during the intervention phase. The TTS is a bachelor’s-level provider who has completed a certified tobacco
treatment training program. If a health system has a dedicated TTS, that TTS will be trained in the Break Free protocol by the study TTS prior to working with Break Free
participants. Four counseling calls are included in Break
Free. During each call, a trained TTS uses motivational
interviewing techniques to bolster intention and confidence around smoking cessation, guide smokers through
a quit attempt and help them strategize for relapse prevention. The TTS tracks participants’ quit date, smoking
cessation outcomes, pharmacotherapy use, and session
content. Side effects of pharmacotherapy are monitored
during counseling calls. Participants whose side effects
are not managed with the usual recommendations (e.g.,
do not wear an NRT patch at night, rotate NRT patches
daily) will be referred to their provider at the clinic. The
TTS will call the clinic to notify the provider that the
participant is experiencing a side effect that is difficult to
manage. If a patient experiences a serious adverse effect
in response to pharmacotherapy, that information will be
conveyed to the study research team and reported to the
IRB.
The Break Free delivery model includes a standard
counseling program for smokers ready to quit in the next
30 days and a modified counseling program for smokers
who are ready to quit in the next 6 months, but not in
the next 30 days. Break Free offers efficacious strategies
[43] regardless of participants’ immediate willingness/
readiness to quit (Table 1). The first Break Free phone
counseling session addresses smoking rate reduction for
all participants. Rate reduction occurs by using strategies such as breaking brand loyalty, self-monitoring, and
disrupting automatic triggers to smoke. The content of
the remaining three phone counseling sessions depends
on whether the participant is ready to quit in the next
30 days or not. Session topics and goals are included
in Table 1. In summary, the standard program guides
a smoker through the quitting process by setting a quit
date and creating a relapse prevention plan. The modified
program includes goals for reductions in the frequency
and amount of smoking between each call.
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Table 1 Break Free protocols for smokers ready to quit immediately and within 6 months
Session # Standard—quit within 30 days

Rate reduction—Quit within 1–6 months

1

Baseline tobacco use and assessment of tobacco history
Rate reduction by 25%
Rate reduction strategies, including, situational control (smoke in only certain situations or never smoke in others), temporal control (a
time-based strategy), and access (keep cigarettes in an inconvenient spot to avoid “automatic cigarettes”)
Nicotine replacement therapy

2

Set a quit date
Prepare to quit

Rate reduction (additional 25%)
Discuss future quit

3

Evaluate the quit date
Develop short-term relapse prevention plan

Rate reduction (additional 25%; 75% total)
Discuss plans short-term relapse prevention for future quit

4

Develop long-term relapse prevention plan

Rate reduction to reduce amount of each cigarette smoked (e.g.,
marking cigarette with a non-toxic pen to encourage participants to
smoke 50% of each cigarette)
Discuss longer-term relapse prevention strategy for future quit
Encourage targeted future quit date

Break Free also includes pharmacotherapy, prescribed by the patient’s provider and in coordination with the TTS. Together, the patient and provider
decide which pharmacotherapy is the most appropriate treatment. Options include varenicline, bupropion,
or any approved form of nicotine replacement therapy
(NRT). Women with health insurance use their benefit to cover pharmacotherapy costs. For uninsured
women, we have created a voucher system whereby
providers can dispense a voucher for free NRT (gum,
patch, or lozenge) or bupropion with the pharmacotherapy prescription. A local pharmacy provides the
medication and bills the study using an invoicing system. If varenicline or the nicotine inhaler is chosen,

Fig. 2 Hybrid implementation-effectiveness study design

the Enrollment Specialist will complete a Pfizer Inc.
application for free medication.
Hybrid effectiveness‑implementation study design

In this cluster randomized trial, health systems are stratified by state and then randomized in a 1:1 ratio to either
an Early Arm or Delayed Arm. To reduce the risk for
contamination, within each stratum, health systems are
randomized into Early Intervention or Delayed Intervention arms. All clinics within each health system are
randomized to the same condition (Early or Delayed
Intervention). Neither health systems nor study participants are blinded to their intervention assignment.
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Figure 2 outlines the timeline for study implementation and evaluation. Following a planning phase (months
1–23; not shown in the figure), Break Free will be implemented in Early Arm health systems over a 12-month
period. After this 12-month period ends, research staff
will train Early Arm health systems on how to bill for
brief counseling (AAR) and smoking cessation phone
counseling, as well as how to implement Break Free
using their own staff and resources as they transition to
a full sustainability period. During this period, Early Arm
health systems will also learn how to “bundle” all three
Take CARE projects addressing smoking cessation, HPV
vaccination, cervical cancer screening as part of an integrated cervical cancer prevention program disseminated
by clinics. Delayed Arm health systems will initially enroll
female smokers into an observational study, which will
allow estimation of the smoking cessation rate in the target population receiving usual care. This group of women
will serve as the comparison for the “effectiveness” of
Break Free. After 12 months, while the Early Arm health
systems are in the sustainability period, Delayed Arm
health systems will implement Break Free, delivered by
our research staff. After that 12-month period ends, they
too will then shift to a sustainability period. Implementation of Break Free will be evaluated through randomly
sampled patient assessments of provider fidelity to AAR
and, for women enrolled in Break Free TTS counseling,
assessments of TTS fidelity to Break Free counseling.
Early Arm health systems

Eligibility criteria Eligible healthcare systems are those
that provide care to female smokers and are in the Appalachian region of the target states. Eligible providers in
the healthcare systems are those who are directly involved
with patient care (e.g., physicians, advance practice professionals). Eligible patients include women who are: (1)
age 18 to 64; (2) smokers who consume at least five cigarettes per day; (3) ready to quit smoking within the next
6 months; (4) English-speaking; (5) able to participate in
phone counseling; (6) willing to try pharmacotherapy; and
(7) not pregnant.
Procedures The study design procedures of Break Free
include: (1) training providers, Clinic Champions, and
Enrollment Specialists as described above; (2) recruitment and consent of potential participants; (3) provision
of cessation counseling and pharmacotherapy; (4) billing
for services; (5) fidelity assessments; (6) follow-up assessments; and (7) cost-effectiveness assessments. All study
protocols were developed with and reviewed by a Community Advisory Board, External Scientific Advisory
Board, and Data and Safety Monitoring Board.
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Trainings: As previously described, all providers from
participating clinics who are directly involved in patient
care will be trained in Break Free and the AAR method.
Trainings will take place in-person or virtually. The training materials were adapted from Rx for 
Change®, an
organization that disseminates public use smoking cessation resources for healthcare providers [40]. In addition,
providers will receive pocket cards (see Additional file 1)
to remind them of Break Free eligibility criteria and pharmacotherapy options for smoking cessation.
All who attend the provider training will be asked to
complete a consent form and pre-training assessment.
Questions focus on attitudes, confidence, and practices around evidence-based smoking cessation treatment; knowledge of counseling and pharmacotherapy
for smoking cessation; and demographics. Immediately
after the provider training session, all participants who
provided consent and completed the pre-training survey
will be asked to complete a post-training survey to assess
increased knowledge following the training. Provider
surveys will also be distributed at the end of the implementation phase, with similar questions as the baseline
survey plus items to assess acceptability and satisfaction
with AAR models and Break Free specifically. Providers
who complete virtual trainings will be sent a link to an
online informed consent prior to completing an online
survey.
Recruitment, Enrollment, and Consent of Participants: Figure 3 outlines the process for participant
recruitment and enrollment into the early arm intervention. Eligible patients will be identified during routine
clinic visits. Providers will ask patients about tobacco use
and advise smokers to quit. Women who are interested
in quitting within the next 6 months and are eligible for
Break Free will receive a prescription for pharmacotherapy and referral to the Enrollment Specialist for that
clinic or health system. The Enrollment Specialist will
introduce potential participants to the Break Free program, distribute the patient educational materials, and
collect patient contact information for referral to the
study-specific TTS to be consented into the study.
Within a week, the study-specific TTS will contact
potential participants and obtain verbal informed consent. If the TTS is unable to reach the potential participant, they will attempt to reach them up to ten times to
schedule the informed consent and baseline assessment.
Consented participants’ contact information is entered
into RedCap data management system for secure storage. Contact information is used to connect participants
to Break Free phone counseling calls and for follow-up
assessments. All participants are assigned a subject ID,
which is stored in RedCap independently from participant data. After consent is obtained, the study
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Fig. 3 Early Intervention Process Map

specific-TTS will administer the baseline assessment via
phone. Participants will receive $10 for completing the
baseline assessment.
Counseling and pharmacotherapy: The Break Free
4-session counseling protocol begins after the baseline
assessment is complete. The study-specific TTS will
counsel participants from health systems that do not

have a dedicated TTS on staff; otherwise, the health system’s TTS will perform the counseling. Again, if the TTS
is unable to reach participants for a counseling session,
they will call them up to ten times to reschedule. If a participants’ phone number is not working, then the TTS
will send a follow-up email and, if needed, a mailed letter,
to update participant contact information.
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Fidelity assessments: Fidelity to the intervention by
providers and the TTS will be assessed separately. To
assess provider fidelity to the AAR model, each quarter
during a 1-week period, all patients who visit the clinic
will be asked to complete an anonymous, self-report,
post-provider visit survey. Paper surveys will be collected
in a sealed envelope by the check-out staff person at the
clinic and mailed to the study team by the Clinic Champion. Patients will also have the option to complete an
online survey by scanning a QR code.
To assess TTS fidelity to Break Free, ten percent of all
Break Free participants will be randomly selected and
called after a scheduled counseling call to confirm the
call occurred and to determine which content was discussed. No financial or other incentives are given for the
fidelity assessments.
Patient follow-up assessments: Break Free participants
will be contacted at 3-, 6-, and 12-months post enrollment to assess current tobacco use and quit attempts
via online or phone surveys. Participants will receive
a $10 gift card incentive for completion of each followup survey. Two weeks prior to each follow-up survey,
participants will be sent a proactive reminder email or
mailed letter reminding them of the upcoming follow-up
assessment.
Delayed Arm health systems

While the Early Arm health systems are in the Early
Intervention phase, the Delayed Arm health systems
will continue usual care (Fig. 1). During this phase, to
determine “usual care” tobacco-related outcomes in the
Delayed Intervention arms, providers will ask eligible
female smokers about their tobacco use and assess readiness to quit. Female smokers who are interested in quitting in the next 6 months will be asked to participate in
this observational component of the study. Those who
agree to participate will be given either a paper a baseline
survey packet with a consent script to sign and the baseline survey in the clinic, where they will be asked to complete it in the clinic and then mail it to the research team
(a self-addressed stamped envelope will be included), or
an online link with an electronic consent and survey. The
consent will include language about follow-up surveys at
3, 6, and 12 months. Study staff will call or email Delayed
Arm participants at 3-, 6-, and 12-months post-baseline
to assess smoking behaviors. Participants will receive
a $10 gift card incentive for completion of each survey.
Once Delayed Arm clinics begin the Active Intervention
phase, they will follow all procedures implemented in
Early Arm health systems as described above.
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Sustainability

Throughout the implementation phase, the study team
will periodically meet with health system representatives and clinic managers to develop practical solutions
to manage any additional clinical burden. With the transition of the Early Arm health systems to sustainability,
the study-specific TTS will no longer provide counseling.
Rather, health systems will need to have their own TTS
(whether established or newly hired) to deliver counseling to sustain the Break Free program. An important
component of sustainability will be recovering maximum
allowable costs for smoking cessation counseling from
health insurers. Thus, providers will be trained on how
to bill insurance companies for tobacco cessation counseling. In the sustainability phase, current billing and
pharmacotherapy practices of each health system, potential barriers in optimizing reimbursement, and their
potential solutions will be documented. The Biostatistics
and Evaluation core will assist in data extraction for these
measures.
Prior to the sustainability period, the other two interventions that are part of Take CARE (addressing HPV
vaccination and cervical cancer screening) will be “bundled” with the Break Free smoking cessation intervention
as part of a multifaceted cervical cancer prevention program. We will provide a refresher training for all clinic
staff and providers that reviews how to implement all
three interventions with patients. We will also train clinic
staff and providers on how to bill for services provided
specific to all three interventions.
Program evaluation

Take CARE program evaluation will include documentation and monitoring of implementation (process evaluation), assessment of progress in reaching goals and
objectives (outcome evaluation), and the extent to which
interventions are adopted by clinics and sustained over
time (sustainability evaluation). Consequently, the Survey and Data Collection and Biostatistics and Evaluation
cores will support evaluation for each of the three Take
CARE initiatives separately as well as the Take CARE
program overall. Evaluation at the overarching program
level, will investigate the relative contributions of individual, community, clinic, and intervention effects on
uptake of the three Take CARE initiatives by participating clinics. For this study protocol, we present detailed
information on the Break Free project evaluation,
including measures, sample parameters, and statistical
analyses.
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Process, outcome, and sustainability measures
Process evaluation

Provider outcomes Acceptability of the Break Free
intervention will be examined by estimating adoption by
providers and staff. These provider-level outcomes will
include self-reported changes in the delivery of AAR and
the rate of referrals to the in-clinic TTS.
Patient outcomes Fidelity to the intervention will be
assessed two ways. First, 10% of women will be randomly
selected and called by a study staff person the day after
Break Free cessation phone counseling and asked standardized questions about the content of the call. Second,
self-administered, anonymous patient post-visit surveys
will be completed throughout the implementation phase.
These fidelity surveys will ask patients to report whether
the provider: (1) asked about tobacco use; and if a smoker,
(2) advised the individual to quit; (3) discussed cessation;
and (4) referred the smoker to counseling. The proportions of patients being asked, advised, and referred are the
outcomes.
Outcome evaluation

Provider outcomes The primary outcome among providers is adoption of the AAR components, measured
by self-report on the provider survey administered at
the end of the implementation phase. We will also assess
responses to the knowledge items on the survey (pre vs.
post-training, and follow-up).
Patient outcomes The primary outcomes among Break
Free patient participants include self-reported: (1) 7-day
point prevalence abstinence; (2) 7-day floating abstinence
during any period since last assessment; (3) prolonged
abstinence (no smoking after a 2-week grace period after
the quit date); and (4) at least one 24-h quit attempt. A
24-h quit attempt is an important endpoint given that it
is associated with a greater likelihood of future cessation
[39]. Secondary outcomes among Break Free participants
include use of pharmacotherapy and number of counseling sessions completed.
Sustainability evaluation

Sustainability will be measured by: (1) documentation
of patient tobacco use status in the EHR; (2) TTS selfreport of continued smoking cessation counseling; and
(3) billing-related documentation of number of counseling sessions billed for overall and for each smoker who
has at least one Break Free counseling session. The Survey and Data Collection core will support EHR and billing data extraction. With the support of the Biostatistics
and Evaluation core, we will also assess cost-effectiveness
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by considering costs of each component including pharmacotherapy, clinic counselor time and training, smoking cessation counselor time and training, telephone and
material costs, and other administrative costs.
Sample size and power analysis

The sample size for the primary outcome (i.e., smoking
cessation among female smokers) is 51 female smokers
per health system, for a total of 510 participants. This
sample size is based on a two-sample test of the 7-day
point prevalence abstinence at 6 months with power calculated using a standard cluster randomized design formula [44]. Assuming a 10% quit rate in the delayed group,
a 25% quit rate in the early intervention group, and a conservative estimate of the intraclass correlation of 0.017, a
total of 10 health systems, equally randomized to Early
and Delayed Intervention groups, a total of 43 smokers
per health system will provide 80% power at a two-sided
significance level of 5%. The sample size was inflated to
51 smokers per health system (or 510 total) to account
for an estimated 20% dropout.
Statistical analyses
Missing data

We recognize that despite efforts to minimize dropout
and missing data, there will be subjects who miss assessments or drop out of the project prior to completion. To
avoid biases due to relationships between dropout and
patient characteristics, we will use multiple imputation
methods appropriate for multilevel data [45] to impute
missing outcomes. Imputation models will include health
system, intervention group, and any patient factors that
differ between those who dropped out and those completing the study. The number of imputed data sets will
equal the dropout percentage as recommended by White
and colleagues [46]. Results from the imputed data sets
will be combined using Rubin’s rules [47].
Provider outcomes

For all provider outcomes, we will conduct intent-totreat analyses (ITT), such that all participants who are
randomized will be included in statistical analyses.
Mixed logistic regression models, with random effects
for provider and clinic, will be used to assess the proportion of patients receiving AAR over the time periods
pre-intervention, during intervention and in the postintervention periods.
Mixed models will be used to assess measures of staff
and provider satisfaction with the program, using random effects for health system. Subsequent analyses will
add provider characteristics in order to evaluate whether
satisfaction with Break Free differs by these characteristics. Mixed models will be used to evaluate changes in
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provider knowledge and attitudes over time, using random effects for health system.
Patient outcomes

For all patient outcomes, we will conduct ITT analyses.
We will assume that non-responders to surveys will be
continued smokers.
Hierarchical (mixed) models will be used to compare smoking cessation outcomes at 6- and 12-months
between female smokers in the Early and Delayed Arm
health systems. Logistic models will be used for the
binary outcomes, including the point prevalence, floating and prolonged abstinence, and at least one 24-h quit
attempt. Subsequent analyses will adjust for patient-level
characteristics in comparing smoking cessation at 6 and
12 months among patients in the Early and Delayed Arm
health systems.
Mixed models will be used to assess measures of participant satisfaction with Break Free, using random effects
for health system and primary provider. Subsequent analyses will add patient characteristics in order to evaluate
whether satisfaction with the Break Free program differs
by these characteristics.
Cost‑effectiveness

A cost-effectiveness analysis will be performed at the end
of the implementation phases. Costs of each component
of Break Free will be tracked, including pharmacotherapy,
patient liaison time and training, TTS time and training, telephone and material costs, incentives, and other
administrative costs. We will value the costs of each
activity using standard costs. Cost-per-quit estimates will
be calculated.
Sustainability

We will track the rate at which women are referred to
counseling and the billing for cessation counseling. Initial analyses will use hierarchical models for count data,
more specifically, negative binomial regression models,
to estimate the trends over time. Subsequent analyses
will use ‘interrupted time series analysis’ [48] to track the
changes in rates of referrals and billing for smoking cessation over time. These analyses will estimate the effect of
policy changes at the health system and health center levels on these rates, accounting for the longitudinal design
and for potential seasonal cycles in referrals and smoking
cessation counseling.
Data management and monitoring

Outcome measures (smoking-related, provider, sustainability) will be obtained from self-administered patient
surveys (in clinic, online) and TTS-delivered phone
assessments, provider surveys (in clinic, online), and
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review of medical charts using electronic health records.
We will use REDCap as our data entry system for these
data.
A Data and Safety Monitoring Board (DSMB) for the
overarching Take CARE program will review protocol
and monitor study progress and outcomes, make recommendations, and ensure that data and human safety
requirements are met. The DSMB is comprised at least
five individuals, including clinicians and researchers
experienced in implementation science, clinical trials,
and cervical cancer; a clinical biostatistician, and a layperson patient advocate. No members of the DSMB is
associated with the three initiatives that comprise the
overall Take CARE research program.

Discussion
Break Free is one component of a comprehensive, integrated program to reduce the burden of cervical cancer
incidence and mortality in Appalachia through interventions delivered in diverse primary care clinics across
four states. The broader program, Take CARE, focuses on
rural Appalachia, an area with high cervical cancer burden [3, 4] and significant barriers to accessing traditionally provided cervical cancer preventive services [8, 9, 16,
18, 49].
A significant strength of Break Free is that the program
is easily adapted to unique clinic settings and varying
available resources. For example, in smaller clinics with
fewer staff, there may not be adequate staffing to establish a Break Free Enrollment Specialist to meet with
patients after provider referral. In these cases, patients
may be referred directly by the provider to the TTS. Successful implementation of Break Free in rural Appalachian health systems has potential to create a sustained
impact on health at the population level by improving
rural patients’ access to high quality, culturally sensitive,
and locally sourced evidence-based smoking cessation
treatment. By the end of this study, staff and providers
in each health system will be trained in how to deliver
and bill for brief provider-delivered cessation counseling
(i.e., AAR). Health systems will also have their own TTS
trained to deliver Break Free phone counseling plus pharmacotherapy to their patients. If successfully shown to
be sustainable, Break Free could be disseminated widely
in clinics within Appalachia to any and all patients who
smoke, across heterogeneous levels of readiness to quit,
as well as to healthcare systems in other underserved
geographic settings or patient populations.
In this study, we applied Break Free, a clinic-based
smoking cessation program, to reduce cervical cancer
risk among women in Appalachia; however, because
smoking is a leading cause of chronic disease and cancer
morbidity [22], Break Free has the potential to impact
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chronic disease and cancer outcomes beyond cervical
cancer. This is especially salient for Appalachia where
rates of tobacco-related disease mortality, including cancer, heart disease, and chronic obstructive pulmonary
disease [50] are disparately high compared to the US
population. Alarmingly, the declines in cancer and heart
disease mortality rates observed across the US over the
past decade are less evident in Appalachia [50]. Increasing tobacco cessation among Appalachian residents, and
especially those in rural areas, could substantially reduce
chronic disease incidence and mortality in this population with high health disparity. Future research might
extend assessment of effectiveness of Break Free to other
groups such as Appalachian men who smoke [14], or
with other high-risk Appalachian populations (e.g., lesbian, gay, and bisexual people [51–54]) wherein smoking
is a persistent disparity.

Limitations
Despite efforts to minimize bias, there are limitations to
this planned study. First, results may be subject to observation bias, as clinics in this cluster randomized trial are
unblinded after baseline assessment. Second, smoking
behavior and cessation outcomes are measured by selfreport, and participants’ responses may be influenced
by social desirability. Self-report measures are a practical compromise. While biochemical validation or data
from EHRs documenting smoking status would be considered a “gold standard” for tobacco studies, neither are
especially practical for researchers or partner clinics. The
Break Free study is designed to assess the effectiveness
of a well-established intervention that combines behavioral counseling with pharmacotherapy. Also, biochemical verification of smoking status is not always needed in
pragmatic randomized control trials [55] and has lower
response rates than self-report data [56]. Third, missing
data can be an issue in trials with longitudinal designs;
however, the planned 6- and 12-month follow-up is consistent with current recommendations for smoking cessation studies [56] and the planned analyses will follow
intent-to-treat methods to minimize bias from dropout
over time. Finally, beyond collecting information about
each clinic’s specific EHR, including any existing processes to identify tobacco users, clinic-level data on other
variables that may affect implementation of Break Free
(e.g., smoking rates of clinic providers and staff, access to
smoking cessation for clinic employees) will not be collected in this study.
Generalizability
This study assesses the effectiveness and implementation
of a smoking cessation program delivered in primary care
clinics across four Appalachian states. While Appalachia
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is a unique geographic and cultural region, its residents
experience barriers to smoking cessation—including
pro-tobacco norms, low provider knowledge and selfefficacy, minimal access to evidence-based counseling
and affordable pharmacotherapy—that are also evident in
non-Appalachian, rural geographic regions in developed
countries [57–59]. The provider training program uses
public use educational materials and the smoking cessation protocol is based on the recommendations included
in the Clinical Practice Guideline [23]. To this end, it is
possible the planned protocol and results from Break
Free may be applied to develop and test multilevel, clinicbased smoking cessation interventions in other rural
regions and countries other than the US (Fig. 3).

Conclusion
Smoking rates in Appalachian regions are among the
highest in the US and because smoking continues to
decline in urban regions, rural-to-urban disparities are
widening [60]. The Clinical Practice Guidelines recommend that healthcare systems adopt institution-wide
changes to promote smoking abstinence among patients
[23]. Break Free is designed to assess the effectiveness
and implementation of three Clinical Practice Guideline
recommendations to implement: (1) a tobacco user identification system at the clinic level; (2) provider-delivered
brief counseling plus referral to supportive cessation services; and (3) a smoking cessation program that includes
behavioral counseling and pharmacotherapy. The overall
goal is to decrease cervical cancer morbidity and mortality in Appalachia by increasing tobacco cessation among
women who smoke, a high-risk population for cervical
cancer, as part of a larger program to address the elevated
rates of cervical cancer in Appalachia.
Contributions to the literature
• This protocol describes Break Free, Project 1 of Take
CARE (P01 CA229143), an integrated cervical cancer
prevention program designed to address three modifiable risk factors for cervical cancer in Appalachia:
cigarette smoking, low rates of HPV vaccination, and
low rates of cervical cancer screening.
• This protocol is an example of a hybrid effectiveness
implementation study design for a tobacco cessation program implemented into healthcare clinics in
Appalachia, where both smoking rates and cervical
cancer rates are high.
• The Break Free program offers clinics in Appalachia
an integrated process for supporting goals of reducing smoking rates among its patients via office system
strategies to identify current tobacco users, disseminate evidence-based smoking cessation treatment,
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and provide clinics with tools to support the sustainability of the program.
• This study protocol uses the implementation science framework and a cluster randomized trial study
design to examine (1) effectiveness of Break Free, (2)
provider and patient satisfaction with Break Free, and
(3) sustainability of Break Free.
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